Exiqon A/S Today Announces a Grant of License to Roche D...(. We aim to achieve this throughimproved...)

Date:10/1/2008

. We aim to achieve this through improved diagnosis: by using diagnostic tests that analyses the genetic profile of each patient's tumor, we can help optimize the treatment selection for the individual patients. Exiqon is uniquely positioned to develop such new diagnostic tests, and we possess the necessary technology. The technology is referred to as LNA(TM). Using this technology, over a period of only four years Exiqon has been able to establish a position for itself as one of the market's leading providers of research products for gene expression analysis.

Our research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other disorders such as neurological disorders and metabolic diseases. We are currently developing our new molecular diagnostic products, and the first new product based on the LNA(TM) technology is scheduled for launch by the end of 2008. A number of new products will follow in the years ahead. Exiqon already has a significant market presence through its existing diagnostic product sales to hospitals in the USA. Through Oncotech, Exiqon markets diagnostic products that enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and helps them select an efficacious treatment. Oncotech is the market leader when it comes to selling such diagnostic tests based on an analysis of fresh tumor tissue. Exiqon plans to use Oncotech's leading market position to sell our new molecular diagnostic products based on the LNA(TM) technology.

Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+).

About RealTime PCR

Real Time PCR (Polymerase Chain Reaction) is the most widely used technology for gene expression analysis and is applied in bo
'/>"/>

SOURCE Exiqon A/S Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related biology technology :

1. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
2. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
5. Exiqon: Major Shareholder Announcement
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
11. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008